KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Current Assets (2016 - 2025)

Thermo Fisher Scientific's Current Assets history spans 17 years, with the latest figure at $28.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 29.68% year-over-year to $28.7 billion, compared with a TTM value of $28.7 billion through Dec 2025, up 29.68%, and an annual FY2025 reading of $28.7 billion, up 29.68% over the prior year.
  • Current Assets for Q4 2025 was $28.7 billion at Thermo Fisher Scientific, up from $22.3 billion in the prior quarter.
  • The five-year high for Current Assets was $28.7 billion in Q4 2025, with the low at $17.7 billion in Q2 2021.
  • Average Current Assets over 5 years is $22.3 billion, with a median of $22.7 billion recorded in 2023.
  • Year-over-year, Current Assets skyrocketed 38.84% in 2021 and then fell 21.94% in 2022.
  • Tracing TMO's Current Assets over 5 years: stood at $20.1 billion in 2021, then rose by 25.44% to $25.2 billion in 2022, then dropped by 2.54% to $24.6 billion in 2023, then decreased by 9.97% to $22.1 billion in 2024, then grew by 29.68% to $28.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Current Assets are $28.7 billion (Q4 2025), $22.3 billion (Q3 2025), and $24.6 billion (Q2 2025).